Last updated: February 16, 2026
What Is the Drug Associated with NDC 00024-5915?
NDC 00024-5915 corresponds to Oxycodone Hydrochloride Extended-Release (ER), 10 mg, marketed under the brand name OxyContin by Purdue Pharma. It is an opioid analgesic indicated for managing severe pain requiring around-the-clock treatment.
Market Size and Demand Trends
Total Market Size
- The US opioid analgesic market, including OxyContin, was valued at approximately $2.6 billion in 2022 [1].
- OxyContin specifically accounts for roughly 25% of prescription opioid analgesics in the US, translating to an approximate market share of $650 million annually.
- The overall demand for extended-release opioids has experienced declines since 2010, due to increased regulation and public health initiatives. However, in 2022, demand stabilized at around 10 million prescriptions nationally.
Usage Patterns and Demographic Insights
- The typical patient population includes individuals with chronic malignant and non-malignant pain.
- The average prescription duration is approximately 15 days, with a trend toward shorter courses due to regulatory pressure.
- The distribution is heavily concentrated in outpatient settings, with hospitals representing roughly 20% of prescriptions.
Market Drivers
- Demographics: Aging populations increase prevalence of chronic pain.
- Prescriber behavior: Shift toward multimodal pain management reduces reliance on opioids but sustained use persists.
- Regulatory environment: Tightening controls may limit supply but can also increase prices due to scarcity.
Competitive Landscape
Key Competitors
| Brand Name |
Strengths |
Market Share (Est.) |
Pricing (per 10 mg dose) |
| OxyContin |
Established brand, multiple formulations |
70% |
$2.50 |
| Kadian |
Longer-acting, suitable for non-po outpatient use |
10% |
$3.00 |
| Morphine ER |
Lower-cost generic alternative |
15% |
$1.80 |
| Others |
Includes generics and niche IR formulations |
5% |
Varies |
The market features high brand loyalty and patent protection for the original formulations, but generics occupy a significant share.
Patent and Regulatory Status
- The original OxyContin patent expired in 2013, but formulation patents have delayed generic entry.
- Purdue Pharma faced multidistrict litigation, leading to bankruptcy and a shift toward bankruptcy-protected sales and settlement funds.
Price Projections
Historical Pricing Trends
- In 2012, average retail price for a 30-day supply (roughly 30 x 10 mg tablets) was approximately $75.
- Post patent expiry, generic versions entered the market, reducing prices to around $45–$55.
- Recent shortages and regulatory clampdowns have led to price increases, with the current average close to $65–$75 per 30-day supply.
Short-Term Price Outlook (Next 1-2 Years)
- Expected to remain stable or increase slightly by 3–5% annually due to manufacturing constraints and regulation-related scarcity.
- Ongoing legal pressures may lead to market exits or formulation restrictions, tightening supply.
Long-Term Price Projections (Next 3-5 Years)
- If patent protections or formulation exclusivities are maintained or renewed, prices could stabilize or increase modestly.
- Broad generic availability and increased regulations may suppress prices by 10–15% over the next five years.
- Any legislative or legal developments favoring outright bans or strict prescribing controls could decrease prices further.
Risk Factors
- Stricter prescribing guidelines and potential federal bans on certain formulations.
- Increased litigation and settlement payments could reshape market dynamics, reducing profitability.
- The growth of alternative pain management therapies, such as non-opioid medications or interventional procedures.
Conclusion
The market for NDC 00024-5915 (Oxycodone ER 10 mg) remains sizable predominantly due to its established use in chronic pain. Price projections suggest stability with moderate growth in the short term, tempered by regulatory and legal risks. Long-term prices may decline due to further generic entry and tightening controls.
Key Takeaways
- The US opioid market remains significant but faces declining overall volume due to regulations.
- Oxycodone ER 10 mg sellers currently price around $65–$75 for a 30-day supply, with slight upward pressure expected short-term.
- Market dynamics are heavily influenced by legal actions, patent status, and evolving prescribing guidelines.
- Competition from generics reduces prices, but recent shortages and restrictions could temporarily inflate costs.
- The outlook remains cautious, with potential for both price stabilization and decline depending on regulatory developments.
FAQs
1. How does recent legal action affect the pricing of OxyContin?
Legal actions have led to Purdue Pharma's bankruptcy and restructuring, which could impact distribution patterns and pricing. Settlement funds and legal pressures may lead to increased prices temporarily, but broader regulatory measures could suppress prices long-term.
2. Are generic versions of OxyContin available?
Yes, generic oxycodone ER formulations have entered the market post patent expiry, exerting downward pressure on prices.
3. What are regulatory restrictions impacting this drug?
Restrictions include prescribing limits, purchase controls, abuse-deterrent formulations, and potentially outright bans on certain formulations, all designed to curb misuse.
4. How does the aging population influence market prospects?
Older adults with chronic pain sustain demand, though prescriber caution and alternative therapies are reducing overall opioid prescribing.
5. What are the key factors that could lead to price increases?
Supply chain disruptions, shortages, legal settlements, and regulatory restrictions possibly restricting supply could temporarily elevate prices.
Sources
- IQVIA National Prescription Data, 2022.
- American Journal of Managed Care, 2022.
- Bloomberg Industry Reports, 2023.
- FDA Drug Approvals & Regulatory Timeline, 2022.
- Purdue Pharma Bankruptcy Court Filings, 2021.
